Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma

BJU Int. 2015 Jun;115(6):854-5. doi: 10.1111/bju.12922. Epub 2015 Jan 21.

Authors

Guru Sonpavde^{1

2}, Gregory R Pond², Ronan Fougeray³, Joaquim Bellmunt^{4

5

6}

Affiliations

¹ UAB Comprehensive Cancer Center, Birmingham, AL, USA.
² McMaster University, Hamilton, Ontario, Canada.
³ Institut de Recherche Pierre Fabre, Boulogne, France.
⁴ Dana-Farber Cancer Institute, Boston, MA, USA.
⁵ Harvard Medical School, Boston, MA, USA.
⁶ University Hospital del Mar-IMIM, Barcelona, Spain.

PMID: 25195625
DOI: 10.1111/bju.12922

No abstract available

MeSH terms

Carcinoma, Transitional Cell / diagnosis
Carcinoma, Transitional Cell / drug therapy*
Humans
Nomograms*
Predictive Value of Tests
Salvage Therapy / methods*
Urologic Neoplasms / diagnosis
Urologic Neoplasms / drug therapy*